Search

Staphylococcus aureus (S. aureus) is a prominent pathogen responsible for mastitis in dairy goats, and capable of contaminating farm environments. Luteolin is a naturally derived flavonoid found in many plant types. To our best of knowledge, this study involved the initial investigation into the prevalence of S. aureus and screened the multidrug-resistant (MDR) S. aureus from raw milk samples and farm environments. Furthermore, we explored the antimicrobial and antibiofilm activities of luteolin against MDR S. aureus. Antibiofilm activity was evaluated via crystal violet staining and confocal laser scanning microscopy (CLSM). Bacterial morphology and biofilm microstructure were observed via scanning electron microscopy (SEM), and the antibiofilm mechanisms were further explored based on extracellular polymeric substance (EPS) production, extracellular DNA (eDNA) content, and quantitative reverse transcription PCR (qRT-PCR). In total, 28 and 43 S. aureus isolates were isolated from raw milk and environmental samples, respectively. Raw milk samples had the highest prevalence of S. aureus (58.33%), followed by sewage sludge (35.42%), soil (27.78%), excrement (19.44%), bulk tank (12.50%), milking parlor (11.11%), and feed (7.50%). Among the isolated strains, 40 isolates (56.34%) expressed the MDR phenotype. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of luteolin against MDR S. aureus were 8–32 μg/mL and 16–64 μg/mL, respectively. Compared to that in the untreated control isolate, the number of dead cells increased, while the auto-aggregation and cell surface hydrophobicity decreased. Moreover, the cell membrane dissolved with the increase in luteolin concentration. Luteolin down-regulated the transcription of seven biofilm related genes: icaA , icaD , icab , hld , hla , agrA and RNAIII. These results indicated that S. aureus coexisted in raw milk and goat farm environments, and also suggested the potential of luteolin as a promising antibiofilm agent against MDR S. aureus. [Display omitted] • Dairy goats infected with Staphylococcus aureus (S. aureus) mastitis may serve as a source of transmission. • Luteolin exerted antibacterial and antibiofilm activity against multidrug-resistant (MDR) S. aureus. • Luteolin could reduce the production of the extracellular polymeric substance and extracellular DNA of MDR S. aureus. • Luteolin could down-regulate the expression of the biofilm related genes. [ABSTRACT FROM AUTHOR]

Colorectal cancer (CRC) is the 3rd most common cancer worldwide. CircRNAs are promising novel biomarkers for CRC. T regulatory (Treg) cells express the immune checkpoint receptor of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and promote tumor immunological tolerance. We therefore investigate the biological functions and mechanisms of circQSOX1 in CRC tumorigenesis; involvement of circQSOX1 in promoting Treg cell-mediated CRC immune escape in anti-CTLA-4 therapy. Bioinformatics analyses were performed for circQSOX1expressions, specific binding sites, and N6-methyladenosine (m6A) motifs of circQSOX1, thatwere further validated with a series of experiments. Functions of circQSOX1 in promoting CRC development, Treg cells-based immune escape, and anti-CTLA-4 therapy response were investigated both in vitro and in vivo. High circQSOX1 expression was associated with carcinogenesis and poor clinical outcome of CRC patients. METTL3-mediated RNA m6A modification on circQSOX1 could be read by IGF2BP2 in CRC cells. CircQSOX1 promoted CRC development by regulating miR-326/miR-330–5p/PGAM1 axis. CircQSOX1 regulated glycolysis and promoted immune escape of CRC cells, and inhibits anti-CTLA-4 therapy response in CRC patients. m6A-modified circQSOX1 facilitated CRC tumorigenesis by sponging miR-326 and miR-330–5p to promotes PGAM1 expression, which further promoted CRC immune escape by activating glycolysis and inactivating the anti-CTLA-4 therapy response of CRC. Combined treatment with sh-circQSOX1 and anti-CTLA-4 could be a strategy to overcome Treg cell-mediated CRC immune therapy resistance. [ABSTRACT FROM AUTHOR]

Lagotis brachystachya Maxim (L. brachystachya) is an herb widely used in traditional Tibetan medicine. In the present study, the antibacterial activity of L. brachystachya extract to extended-spectrum-lactamases (ESBLs)-producing E. coli was determined by Kirby-Bauer disc diffusion, minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) methods as well as time-kill curve assay. Meanwhile, the biofilm inhibition and eradication effects of L. brachystachya extract on the ESBLs-producing E. coli were evaluated by crystal violet staining, and further confirmed by confocal laser scanning microscope (CLSM) and scanning electron microscopy (SEM). The results indicated that L. brachystachya extract exhibited moderate antibacterial activity, with diameter of inhibition zones varying from 15.4 to 20.3 mm, and the MIC and MBC values were 6.25 to 25 mg/mL and 12.5 to 100 mg/mL, respectively. Time-kill curve showed that 4 × MIC level of L. brachystachya extract concentration of was able to kill 99.9% of ESBLs-producing E. coli after 16 h treatment. The biofilm inhibition rate and eradication rate for the ESBLs-producing E. coli were 35.66 to 79.91% and 22.18 to 56.21% at MIC level of extract concentration, respectively. CLSM images showed that the biofilm became thinner as the ESBLs-producing E. coli isolate exposed to L. brachystachya extract with a concentration-dependent manner from 1/4 × MIC to MIC compared with the control isolate. SEM images indicated that L. brachystachya extract at 1/2 × MIC and MIC levels could evidently inhibit the biofilm formation or eradicate the mature biofilms. The effect of L. brachystachya highlights its potential of antibacterial and antibiofilm activities against the ESBLs-producing E. coli. [ABSTRACT FROM AUTHOR]